Ghisallo Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Ghisallo Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40,000	Closed	-$2.05M	–	195
2025 Q1	$2.05M	Buy	+40,000	New	+$1.98M	0.18%	81
2023 Q4	–	Sell	-50,000	Closed	-$889K	–	168
2023 Q3	$889K	Buy	+50,000	New	+$885K	0.09%	88

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Ghisallo Capital Management's TARS Position: Q2 2025 in Review

Ghisallo Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 40,000 shares — an estimated $2.05M sold.

Ghisallo Capital Management first reported a position in TARS in Q3 2023 and held it in 2 quarters. The position peaked at $2.05M in Q1 2025. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

Ghisallo Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Ghisallo Capital Management sold 40,000 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $2.05M.
Ghisallo Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 2 quarters.
Ghisallo Capital Management's Tarsus Pharmaceuticals position peaked at $2.05M in Q1 2025.
205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Ghisallo Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.